Metformin Hydrochloride Tablets

1. Product Introduction

Metformin Hydrochloride is a biguanide antidiabetic medicine widely used to improve glycemic control in people with type 2 diabetes mellitus, alongside diet and exercise. It primarily reduces glucose production by the liver and improves insulin sensitivity. This page covers the supplied immediate-release film-coated tablets in IP and BP grades.

Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter in the supplied product information. Contract manufacturing capabilities, facility certifications and export authorizations should be verified against current documents.

2. Product Specifications

Separate products: Metformin sustained-release tablets and Metformin Hydrochloride + Glimepiride SR 500 mg/1 mg are different formulations and are not included in the compositions above. View Metformin SR · View Metformin + Glimepiride SR.

3. Manufacturing Technology

Immediate-release metformin tablets may be produced using validated granulation or direct-compression processes, followed by film coating. Manufacturing controls address blend uniformity, tablet hardness, disintegration, dissolution and packaging integrity. The actual granulation process, odor-control technology and equipment must be confirmed by the manufacturer rather than assumed.

Sustained-release matrix technology is a separate dosage-form approach and should not be attributed to these film-coated tablets without supporting product documentation.

4. Quality Assurance

Batch release should be assessed against the applicable approved IP/BP specifications, including identification, assay, impurities, dissolution and relevant uniformity tests. Exact acceptance criteria depend on the pharmacopoeial monograph and approved method.

Any NDMA or other nitrosamine testing claims require a current risk assessment and appropriate analytical evidence. Request batch-specific certificates of analysis, stability data and product specifications.

5. Why Use Metformin?

Metformin decreases hepatic glucose production and improves the body's response to insulin. It generally does not cause hypoglycemia when used alone and is often weight-neutral or associated with modest weight reduction.

Primary indication: Type 2 diabetes mellitus. Use in prediabetes or polycystic ovary syndrome (PCOS) may be off-label or depend on local guidance. Pregnancy-related treatment decisions require individualized specialist assessment; metformin should not be described as universally preferred for gestational diabetes.

6. Export and Regulatory Support

Business customers may request current GMP documentation, Certificate of Analysis, approved artwork, stability data, product registration status, and dossier availability (CTD/ACTD where applicable). COPP, Free Sale Certificate, bioequivalence evidence and export permissions should be confirmed for each destination market before making commercial or regulatory claims.

7. Frequently Asked Questions

Q: Which strengths are confirmed?
A: IP 500 mg and 1000 mg; BP 500 mg and 850 mg.

Q: Is Trippleace Metformin-500 a combination medicine?
A: The supplied label describes Metformin Hydrochloride BP 500 mg alone.

Q: Does metformin cause low blood sugar?
A: Hypoglycemia is uncommon when metformin is taken alone, but the risk can rise when combined with insulin or sulfonylureas.

Q: Why can it cause diarrhea?
A: Gastrointestinal effects such as diarrhea and nausea are common, particularly when starting treatment; taking it with meals and gradual dose adjustment may improve tolerability.

8. Dosage and Administration

Immediate-release metformin is generally taken with meals, often in divided daily doses. Starting dose, titration, maximum dose and any change to extended-release formulations depend on the approved label, kidney function, blood glucose response and clinician judgment. Do not use the strength of an available tablet as a self-directed starting dose.

9. Side Effects and Precautions

• Common: diarrhea, nausea, abdominal discomfort and reduced appetite.
• Lactic acidosis: rare but serious. Risk increases with severe renal impairment, hypoxic conditions, acute illness and excessive alcohol intake.
• Renal monitoring: assess eGFR before and during treatment. Metformin is contraindicated when eGFR is below 30 mL/min/1.73 m²; initiation at eGFR 30–45 is generally not recommended under US labeling.
• Vitamin B12: prolonged therapy may reduce levels; assess when clinically indicated.
• Iodinated contrast: some patients require temporary withholding for particular imaging procedures; follow prescriber and radiology instructions.
• Drug combinations: insulin or sulfonylureas can increase hypoglycemia risk.

10. Storage Instructions

Store in original packaging, protected from excessive heat and moisture, according to the approved product label. A specific temperature limit and shelf life must be supported by validated stability data.